MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD

MedXY Editorial Team•Aug 14, 2026•Gastroenterology
MASLDcardiovascular-kidney-metabolic syndromeliver fibrosisliver-related events

Highlight

  • The cardiovascular-kidney-metabolic (CKM) syndrome framework integrates dysfunction in cardiovascular, renal, and metabolic systems relevant to MASLD progression.
  • Advanced CKM stages correlate with increased prevalence and progression of liver fibrosis in MASLD patients.
  • CKM stage 3-4 significantly elevates the risk of liver-related clinical events, while stage 2 primarily drives liver stiffness progression.
  • Understanding CKM syndrome may aid clinical risk stratification and targeted management of liver disease in MASLD.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Saroglitazar Shows Promise in Treating Hepatic Steatosis in Women with PCOS and MASLD: Insights from a Multicenter TrialSaroglitazar significantly improves liver fat content, liver enzymes, and lipid profiles in women with PCOS and MASLD, highlighting its potential as a therapeutic option in this underrepresented population.Oct 21, 2026Impact of Poor Food Access on Metabolic Dysfunction-associated Liver Disease and Frailty Among Liver Transplant Candidates: A Geospatial AnalysisPoor food access correlates with higher MASLD and frailty prevalence in liver transplant candidates, with geospatial clustering highlighting socioeconomic and environmental determinants impacting transplant candidacy and outcomes.Oct 15, 2026Modulating MASLD Risk in PNPLA3I148M Carriers: The Role of Gut Microbiota and CeramidesGenetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) is amplified by gut microbiota interactions, with ceramides playing a key role; targeted microbial interventions can reverse hepatic injury in at-risOct 10, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Head-to-Head Comparison of Empagliflozin and Dapagliflozin on Liver Outcomes in Type 2 Diabetes with MASLD
A large Korean cohort study found similar hepatic benefits between empagliflozin and dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, with no difference in risk of severe liver com
Oct 5, 2026
Unveiling the Role of Butyrylcholinesterase in Hepatic Fibrosis: A Novel Cholinergic Target in Liver DiseaseButyrylcholinesterase (BuChE) modulates hepatic stellate cell activation by degrading acetylcholine, mitigating fibrogenesis via muscarinic receptor signaling and offering a new therapeutic target for liver fibrosis.Sep 28, 2026
Parental Obesity and the Adult Offspring’s Risk of Metabolic Dysfunction Associated Steatotic Liver Disease: Insights from a UK Birth Cohort StudyThis UK cohort study reveals that both maternal and paternal obesity before pregnancy significantly increase offspring’s risk of metabolic dysfunction associated steatotic liver disease (MASLD) by age 24, largely mediated by excess chSep 17, 2026